ARTICLE | Clinical News
MOGN, MethylGene begin MG98 Phase II
August 21, 2001 7:00 AM UTC
MGI Pharma (MOGN) and MethylGene (Montreal, Quebec) began a Canadian Phase II trial of the companies' MG98 DNA methyltransferase antisense inhibitor in up to 30 patients with advanced and/or metastati...